It has been several years since eliquis was approved as an oral anticoagulant but still more research is being done to show its benefits in helping patients with non-valvular atrial fibrillation.
Eliquis is an oral antic and that is indicated the risk of stroke and system as well as to reduce dvts and bees and treat dvt and pe have over seventeen abstracts that are being presented across our program so we have an expanse program which encompasses randomized clinical trials large phase three trials and representing sub analysis of the data in addition we’re
Presenting phase four studies so we actually are presenting a study design and rationale on one of our studies an af acs which is a very interesting scientific area that we’re exploring with a pics of em or eliquis and in addition we have a twelve random real world data presentations of which eight eight are comparative rural data presentations versus other oral
Anticoagulants so we’re very excited because this all falls under the umbrella of acropolis which is our large our our large global real world data program that we’re launching here at acc this medications been approved for a few years and as part of the medical scientific community we are trying to generate more evidence for our physicians to be able to to jen to
To be able to make informed decisions based on the data that we’re generating for their patients i think when it comes to real-world data we’re really excited because we’re showing that when you actually reduce the risk of bleeding versus warfarin and this is something that we’ve shown in our randomized clinical trials but now we’re able to show that even outside
Of the typical randomized clinical trials so i think this shows physicians that the data that they sign these large studies are actually very complementary to what we’re already seeing now even in that clinical practice setting so physicians always want to know well how does eliquis world work outside of the senior control setting and that’s what the real world
Data program offers evidence and what we’re showing today is it’s actually very supportive and complimentary of what we saw in the clinical trial well data is not going to lead to new indications i think for that our regulative regulators expect us to generate data in a more controlled setting but for our physicians this additional data offers a large database
Set so typically our large phase three trial has maybe 18,000 patients here we’re looking at a very large setting almost three hundred seventy thousand patient records of which 50,000 of them are just with a pixel ban and that gives patient and that gives the physicians that confidence that okay what you saw in this very nice control setting is building upon this
Wall of evidence with their arm randomized with their real-world data that we’re showing today i think the short answer – that is yes so yes physicians know warfarin but in the last decade we’ve able to bring two to them a new class of medicines the oral anticoagulants which don’t have to be monitored which are easier on patients and even more importantly in our
Four eliquis for example in our large phase three trial we showed that we had lower risk of bleeding versus warfarin and we also showed that we are doing what we want the drug to do which is to reduce the risk of stroke in patients with atrial fibrillation versus warfarin so we’re providing a medicine that’s actually safer and more effective then the the drug
That they’re used to in addition we’re building upon a lot of evidence that we’re seeing in rural data back to what we’re presenting here at acc which doesn’t necessarily exist from a warfarin stand-alone perspective and now here today we can show that even physicians across the globe that are using eliquis are seeing the same evidence versus warfarin of reduction
In bleeding and that for a physician is helping them to understand the benefit and the value that this medicine is bringing to their patients valvular af absolutely the only the indication would be to use warfarin because in our studies we excluded those patients although we had a few patients that were included we still are indication is for non valvular atrial
Fibrillation we do conduct a lot of research it’s called independent research that our thought leaders you know submit proposals and they and they were doing research in areas outside of our current indications but per you know what is within the guidelines and the label we are indicated for nonverbal or atrial fibrillation for the broad spectrum being non valvular
Af and the valvular population is very small and it’s continuing to get even smaller so i think when you look really at the broad population non-valid or af is that broad population and we wanted to study it holistically in that larger population it’s really nice to have a new oral anticoagulants you know you don’t have to monitor the irs or go to your physician
Constantly and check those labs it changes the patient’s lifestyle you know all the oral anticoagulants do cause bleeding and that’s why it’s important that you go back to your randomised clinical trials and you’re able to see that yes it does cause bleeding but it’s less than what you would see with another agent such as warfarin which is what we studied ourselves
And what we continue to study ourselves in a rural data setting
Transcribed from video
Eliquis Continues to Show Positive Results in Real World Trials By HCPLive
